{"id":11006,"date":"2013-10-23T08:32:36","date_gmt":"2013-10-23T12:32:36","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=11006"},"modified":"2013-10-23T08:32:36","modified_gmt":"2013-10-23T12:32:36","slug":"dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006","title":{"rendered":"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)&#8217;s new drug"},"content":{"rendered":"<p style=\"text-align: justify;\">The autonomous organization DMC (Data Monitoring Committee) has advised in October that the part 3 experiment of Gilead Sciences, Inc. (NASDAQ:GILD) new cancer drug idelalisib be reduced as there is clear proof that it was helping patients. Studies carried out have proved that patients who are receiving idelalisib along with another drug, Rituxan (manufactured by Roche), lived more and their cancer did not increase.\u00a0 Gileads drug has already been presented to the FDA for sanction to be used as a a treatment for NHL (non-Hodgkin&#8217;s lymphoma. The company is now thinking of asking the FDA to sanction the drug for treatment of CLL (chronic lymphocytic leukemia). Gilead aims to be a competitor in the area of cancer and the launch of this drug next year will help it achieve that aim.<\/p>\n<p style=\"text-align: justify;\">Though the new drug when it enters the market will be in direct competition with ibrutinib a medicine that has received a lot of publicity for its known capacity to treat leukemia created jointly by\u00a0 Pharmacyclics (PCYC) and Johnson &amp; Johnson (JNJ). This medicine is due to be launched in 2014.<\/p>\n<p style=\"text-align: justify;\">The DMC advice\u00a0 to reduce the experiment time of the medicine was based on a study that showed excellent statistical efficiency and longer living\u00a0 for patients suffering from cancer and being treated with\u00a0 idelalisib and Rituxan. Behind this advise of the DMC which is done in very few cases, it is not right for patients to be treated with a drug which is not\u00a0 up to the mark and now all patients would be able to receive the new drug once it hits the market.<\/p>\n<p style=\"text-align: justify;\">Idelalisib was being created to treat cancer alone or in combination with other drugs. At the moment three other drugs which are with Arzerra from Glaxo (GSK) and Genmab with Rituxan, , and a combination of Rituxan and Treanda (from Teva (TEVA).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The autonomous organization DMC (Data Monitoring Committee) has advised in October that the part 3 experiment of Gilead Sciences, Inc. (NASDAQ:GILD) new cancer drug idelalisib [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":10910,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1978,3626,1522],"stock_ticker":[],"class_list":["post-11006","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-gilead-sciences-inc-nasdaqgild","tag-gilead-sciences-inc","tag-nasdaqgild","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)&#039;s new drug - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)&#039;s new drug - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"The autonomous organization DMC (Data Monitoring Committee) has advised in October that the part 3 experiment of Gilead Sciences, Inc. (NASDAQ:GILD) new cancer drug idelalisib [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-10-23T12:32:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)&#8217;s new drug\",\"datePublished\":\"2013-10-23T12:32:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\",\"keywords\":[\"Gilead Sciences Inc (NASDAQ:GILD)\",\"Gilead Sciences Inc.\",\"NASDAQ:GILD\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006\",\"name\":\"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)'s new drug - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\",\"datePublished\":\"2013-10-23T12:32:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)&#8217;s new drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)'s new drug - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006","og_locale":"en_US","og_type":"article","og_title":"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)'s new drug - Wall Street PR","og_description":"The autonomous organization DMC (Data Monitoring Committee) has advised in October that the part 3 experiment of Gilead Sciences, Inc. (NASDAQ:GILD) new cancer drug idelalisib [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-10-23T12:32:36+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)&#8217;s new drug","datePublished":"2013-10-23T12:32:36+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","keywords":["Gilead Sciences Inc (NASDAQ:GILD)","Gilead Sciences Inc.","NASDAQ:GILD"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006","url":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006","name":"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)'s new drug - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","datePublished":"2013-10-23T12:32:36+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/dmc-advises-fda-to-reduce-experiment-time-for-gilead-sciences-inc-nasdaqgilds-new-drug-11006#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"DMC advises FDA to reduce experiment time for Gilead Sciences, Inc. (NASDAQ:GILD)&#8217;s new drug"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/11006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=11006"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/11006\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/10910"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=11006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=11006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=11006"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=11006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}